Tyche Wealth Partners LLC Acquires Shares of 18,194 Aflac Incorporated (NYSE:AFL)

Tyche Wealth Partners LLC acquired a new stake in shares of Aflac Incorporated (NYSE:AFL) in the 4th quarter, HoldingsChannel reports. The firm acquired 18,194 shares of the financial services provider’s stock, valued at approximately $1,501,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AFL. Norges Bank purchased a new stake in Aflac during the 4th quarter valued at approximately $175,416,000. Invesco Ltd. raised its stake in Aflac by 62.4% during the 1st quarter. Invesco Ltd. now owns 4,936,608 shares of the financial services provider’s stock valued at $317,865,000 after acquiring an additional 1,897,212 shares during the last quarter. Morgan Stanley raised its stake in Aflac by 22.9% during the 4th quarter. Morgan Stanley now owns 8,812,956 shares of the financial services provider’s stock valued at $634,004,000 after acquiring an additional 1,640,984 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Aflac during the 4th quarter valued at approximately $72,249,000. Finally, Barclays PLC raised its stake in Aflac by 67.3% during the 2nd quarter. Barclays PLC now owns 1,712,568 shares of the financial services provider’s stock valued at $119,539,000 after acquiring an additional 689,173 shares during the last quarter. 67.44% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Aflac

In other Aflac news, Director Masatoshi Koide sold 30,493 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the sale, the director now owns 86,090 shares in the company, valued at approximately $6,879,451.90. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Aflac news, Director Thomas J. Kenny sold 5,000 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total transaction of $423,100.00. Following the sale, the director now owns 17,920 shares in the company, valued at approximately $1,516,390.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Masatoshi Koide sold 30,493 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $79.91, for a total value of $2,436,695.63. Following the sale, the director now owns 86,090 shares in the company, valued at approximately $6,879,451.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,493 shares of company stock worth $3,765,706. 0.80% of the stock is owned by insiders.

Aflac Price Performance

NYSE AFL traded up $0.15 during mid-day trading on Tuesday, hitting $80.42. The stock had a trading volume of 2,114,324 shares, compared to its average volume of 2,243,603. Aflac Incorporated has a 52-week low of $64.10 and a 52-week high of $86.26. The company has a market cap of $46.27 billion, a price-to-earnings ratio of 10.38, a P/E/G ratio of 2.20 and a beta of 0.91. The company has a 50 day simple moving average of $81.96 and a 200 day simple moving average of $81.44. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33.

Aflac (NYSE:AFL) last released its quarterly earnings data on Thursday, February 1st. The financial services provider reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.47 by ($0.22). The firm had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $4.44 billion. Aflac had a net margin of 24.92% and a return on equity of 17.59%. During the same period in the previous year, the business earned $1.29 earnings per share. Equities analysts forecast that Aflac Incorporated will post 6.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Raymond James upped their price objective on Aflac from $83.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Evercore ISI downgraded Aflac from an “in-line” rating to an “underperform” rating and increased their target price for the stock from $76.00 to $78.00 in a research note on Thursday, January 4th. The Goldman Sachs Group increased their target price on Aflac from $61.00 to $75.00 and gave the stock a “sell” rating in a research note on Tuesday, January 9th. Keefe, Bruyette & Woods increased their target price on Aflac from $83.00 to $87.00 and gave the stock a “market perform” rating in a research note on Wednesday, April 10th. Finally, Piper Sandler increased their target price on Aflac from $90.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, April 5th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $82.15.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.